Scienture

The company aims to improve patient adherence beyond traditional therapies.

Scienture, LLC is a New York-based pharmaceutical company with a pipeline spanning therapeutic areas, indications, and market segments. Its capabilities include R&D, manufacturing, sales, marketing, and commercial operations.

The company responds to general inquiries within three business days.

Scienture reports a **256% sequential revenue increase** in Q3 2026, reaching approximately **$1.22 million**, driven by growth in its **Arbli™** product. The company highlights **two FDA-approved commercial products** and outlines progress toward achieving **profitability by 2027**. The shareholder letter emphasizes continued revenue momentum and operational advancements as key milestones.

Oct 2026GlobeNewswireNews article

SCIENTURE reports **$1.22 million in unaudited preliminary Q3 2026 revenue**, marking a **256% sequential increase**. Growth stems from continued sales of its **Arbli™** product line and the **August 2026 commercial launch of REZENOPY™**, including initial wholesale shipments. The company highlights these developments as key drivers of its financial performance.

Oct 2026GlobeNewswireNews article

SCIENTURE Holdings adds **Arbli™ Oral Suspension (10 mg/mL)** to the drug formularies of three major U.S. pediatric academic medical centers and hospitals. The move expands access to the novel specialty product for pediatric patients. SCIENTURE develops and commercializes therapies targeting unmet medical needs in specialty care.

Oct 2026nasdaq.comNews article

Scienture Holdings announces a **1-for-25 reverse stock split** to adjust its share price. The move aims to improve liquidity and trading accessibility for investors. The company operates in the life sciences sector, focusing on research and development.

Sep 2026Investing.comNews article